| __timestamp | AstraZeneca PLC | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 205018000 |
| Thursday, January 1, 2015 | 4646000000 | 392709000 |
| Friday, January 1, 2016 | 4126000000 | 299694000 |
| Sunday, January 1, 2017 | 4318000000 | 397061000 |
| Monday, January 1, 2018 | 4936000000 | 434100000 |
| Tuesday, January 1, 2019 | 4921000000 | 782200000 |
| Wednesday, January 1, 2020 | 5299000000 | 1119900000 |
| Friday, January 1, 2021 | 12437000000 | 2437500000 |
| Saturday, January 1, 2022 | 12391000000 | 1560400000 |
| Sunday, January 1, 2023 | 8040000000 | 1815800000 |
| Monday, January 1, 2024 | 10207000000 | 1970500000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. AstraZeneca PLC and Regeneron Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue from 2014 to 2023. AstraZeneca's expenses surged by over 100% from 2014 to 2021, peaking in 2021 with a cost of revenue nearly three times that of 2014. This reflects their aggressive expansion and investment in R&D. In contrast, Regeneron, while starting with a modest cost base, saw a consistent increase, reaching its highest in 2021, marking a 1,100% rise from 2014. This growth underscores Regeneron's strategic scaling and innovation efforts. By 2023, both companies adjusted their spending, with AstraZeneca reducing costs by 35% from its peak, while Regeneron maintained a steady trajectory. These insights highlight the dynamic nature of pharmaceutical financial strategies over the past decade.
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
AstraZeneca PLC vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
Cost of Revenue Comparison: Novartis AG vs Regeneron Pharmaceuticals, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Dr. Reddy's Laboratories Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.